Epocrates http://prod.caas.epocrates.com/ en Lung Cancer Screening in Asymptomatic Pts | USPSTF, ACCP, ACS, AATS, etc Guideline Synthesis http://prod.caas.epocrates.com/e/guideline/10_15 <span class="field field--name-title field--type-string field--label-hidden">Lung Cancer Screening in Asymptomatic Pts | USPSTF, ACCP, ACS, AATS, etc Guideline Synthesis</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/441" typeof="schema:Person" property="schema:name" datatype="">switaschek</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 10/15/2020 - 23:17</span> <div class="field field--name-field-g-title-s field--type-string field--label-above"> <div class="field__label">Title (short)</div> <div class="field__item">Lung Cancer Screening in Asymptomatic Pts</div> </div> <div class="field field--name-field-g-published field--type-boolean field--label-above"> <div class="field__label">Do not Publish</div> <div class="field__item">Publish</div> </div> <div class="field field--name-field-guidelines-specialty field--type-entity-reference field--label-above"> <div class="field__label">Guidelines Specialty</div> <div class="field__items"> <div class="field__item"><a href="/taxonomy/term/2596" hreflang="en">Family Medicine/Primary Care</a></div> <div class="field__item"><a href="/taxonomy/term/2616" hreflang="en">Health Maintenance</a></div> <div class="field__item"><a href="/taxonomy/term/2651" hreflang="en">OB/Gyn</a></div> <div class="field__item"><a href="/taxonomy/term/2681" hreflang="en">Pulmonary Medicine</a></div> <div class="field__item"><a href="/taxonomy/term/2656" hreflang="en">Oncology</a></div> <div class="field__item"><a href="/taxonomy/term/2611" hreflang="en">Geriatric Medicine</a></div> </div> </div> <div class="field field--name-field-rec-title field--type-string-long field--label-above"> <div class="field__label">Key Points</div> <div class="field__item">Low-dose CT (LDCT) is widely accepted; don’t use CXR as screen. Age &amp; risk level thresholds to start/end screening vary: Many recommend starting @ 55 yo in current/former smokers w/ ≥30 pk-yr hx, but USPSTF recommends starting earlier &amp; @ lower smoking hx. Shared decision-making integral to pre-screen discussion on risk/harm balance. Screening doesn’t replace smoking cessation.</div> </div> <div class="field field--name-field-patient-type-labels field--type-string field--label-above"> <div class="field__label">Patient Type Label</div> <div class="field__item">Choose Patient Type</div> </div> <div class="field field--name-field-patient-type field--type-entity-reference field--label-above"> <div class="field__label">Patient Type</div> <div class="field__items"> <div class="field__item"><a href="/node/158881" hreflang="en">Age</a></div> <div class="field__item"><a href="/node/158646" hreflang="en">Age 50 54 yo</a></div> <div class="field__item"><a href="/node/158651" hreflang="en">Age 55 74 yo</a></div> <div class="field__item"><a href="/node/158656" hreflang="en">Age 75 77 yo</a></div> <div class="field__item"><a href="/node/158661" hreflang="en">Age 78 80 yo</a></div> <div class="field__item"><a href="/node/158666" hreflang="en">Age 80 yo</a></div> </div> </div> <div class="field field--name-field-g-reference field--type-entity-reference field--label-above"> <div class="field__label">Reference</div> <div class="field__item"><a href="/node/158821" hreflang="en">Peer reviewed &amp; based on multiple guidelines/recommendations from specialty societies/government agencies</a></div> </div> <div class="field field--name-field-g-celebrity field--type-entity-reference field--label-above"> <div class="field__label">Celebrity</div> <div class="field__item"><a href="/node/159536" hreflang="en">epocrates</a></div> </div> <div class="field field--name-field-g-keywords field--type-string field--label-above"> <div class="field__label">Keywords</div> <div class="field__item">lung cancer,screening lung cancer,screen,lung cancer prevention,tobacco,smoker cancer screen,lung cancer screen,LDCT</div> </div> Fri, 16 Oct 2020 02:17:37 +0000 switaschek 158641 at http://prod.caas.epocrates.com Inhaled Budesonide in the Treatment of Early COVID 19 STOIC A phase 2 Open label Randomised Controlled Trial access Lancet Respir Med article http://prod.caas.epocrates.com/node/184011 <span class="field field--name-title field--type-string field--label-hidden">Inhaled Budesonide in the Treatment of Early COVID 19 STOIC A phase 2 Open label Randomised Controlled Trial access Lancet Respir Med article</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/391" typeof="schema:Person" property="schema:name" datatype="">vgreene</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 09/24/2021 - 12:30</span> <div class="field field--name-field-pt-detail-long field--type-string-long field--label-above"> <div class="field__label">Detail (Long)</div> <div class="field__item">Inhaled Budesonide in the Treatment of Early COVID-19 (STOIC): A phase 2, Open-label, Randomised Controlled Trial; &lt;a href=https://www.thelancet.com/article/S2213-2600(21)00160-0/fulltext&gt;&lt;b&gt;&lt;u&gt;access &lt;i&gt;Lancet Respir Med&lt;/i&gt; article&lt;/u&gt;&lt;/b&gt;&lt;/a&gt;</div> </div> Fri, 24 Sep 2021 15:30:01 +0000 vgreene 184011 at http://prod.caas.epocrates.com Booster dose 1 dose 6mo after primary series in pts 65 yo or 18 64 yo at high risk for severe COVID 19 or frequent institutional or occupational exposure http://prod.caas.epocrates.com/node/184006 <span class="field field--name-title field--type-string field--label-hidden">Booster dose 1 dose 6mo after primary series in pts 65 yo or 18 64 yo at high risk for severe COVID 19 or frequent institutional or occupational exposure</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/391" typeof="schema:Person" property="schema:name" datatype="">vgreene</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 09/24/2021 - 12:27</span> <div class="field field--name-field-pt-detail-long field--type-string-long field--label-above"> <div class="field__label">Detail (Long)</div> <div class="field__item">&lt;b&gt;Booster dose:&lt;/b&gt; 1 dose ≥6mo after primary series in pts ≥65 yo, or 18-64 yo at high risk for severe COVID-19, or frequent institutional or occupational exposure</div> </div> Fri, 24 Sep 2021 15:27:10 +0000 vgreene 184006 at http://prod.caas.epocrates.com A different kind of nasal drip http://prod.caas.epocrates.com/e/docalertquiz/09_20-0 <span class="field field--name-title field--type-string field--label-hidden">A different kind of nasal drip</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/396" typeof="schema:Person" property="schema:name" datatype="">rray</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 09/20/2021 - 20:55</span> <div class="field field--name-field-daq-question field--type-string-long field--label-above"> <div class="field__label">Question Long Text</div> <div class="field__item">(BMJ)—A woman in her 50s with hx of uncontrolled DM presented with nasal obstruction and right facial pain. She was treated empirically for sinusitis, with nasal steroids and saline wash. Ten days later, she presented to the ED, with a black paranasal lesion. What’s the dx?</div> </div> <div class="field field--name-field-daq-image field--type-file field--label-above"> <div class="field__label">Image</div> <div class="field__items"> <div class="field__item"> <span class="file file--mime-image-png file--image"> <a href="http://prod.caas.epocrates.com/sites/epocrates/files/2021-09/09_38_all%20users_BMJ_small.png" type="image/png; length=93078">09_38_all users_BMJ_small.png</a></span> </div> </div> </div> <div class="field field--name-field-daq-correct field--type-string field--label-above"> <div class="field__label">Correct Answer</div> <div class="field__item">Mucormycosis</div> </div> <div class="clearfix text-formatted field field--name-field-daq-filler field--type-text-long field--label-above"> <div class="field__label">Filler Answers</div> <div class="field__items"> <div class="field__item"><p>&lt;p&gt;&lt;span style=&quot;font-size:12pt&quot;&gt;&lt;span style=&quot;font-family:Calibri,sans-serif&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;Cutaneous anthrax&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</p> </div> <div class="field__item"><p>&lt;p&gt;&lt;span style=&quot;font-size:12pt&quot;&gt;&lt;span style=&quot;font-family:Calibri,sans-serif&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;Ecthyma gangrenosum&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</p> </div> <div class="field__item"><p>&lt;p&gt;&lt;span style=&quot;font-size:12pt&quot;&gt;&lt;span style=&quot;font-family:Calibri,sans-serif&quot;&gt;&lt;span style=&quot;background:white&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;Sinonasal sarcoma&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</p> </div> <div class="field__item"><p>&lt;p&gt;&lt;span style=&quot;font-size:12pt&quot;&gt;&lt;span style=&quot;font-family:Calibri,sans-serif&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;Syphilis&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</p> </div> </div> </div> <div class="field field--name-field-daq-response field--type-string-long field--label-above"> <div class="field__label">Response</div> <div class="field__item">Invasive fungal infection was suspected because of the characteristic black appearance of the lesion. Dx was confirmed by isolation of &lt;i&gt;Rhizopus arrhizus&lt;/i&gt; from a bx sample. The patient underwent immediate emergency surgery for debridement, and systemic antifungal tx was started.&lt;br&gt;&lt;/br&gt;<br /> <br /> Acute invasive rhino-orbito-cerebral mucormycosis is a life-threatening fungal infection that occurs in patients who are immunocompromised, such as those with poorly controlled DM (70% of cases). Other predisposing factors include hematological neoplasms, renal transplant, injection drug use, and use of deferoxamine.&lt;br&gt;&lt;/br&gt;<br /> <br /> Because of the rapid progression of this condition, early surgical debridement is imperative to avoid extensive tissue and eye loss and even death.&lt;br&gt;&lt;/br&gt;<br /> <br /> &lt;i&gt;BMJ&lt;/i&gt; 2021;374:n1705<br /> </div> </div> <div class="field field--name-field-source-name field--type-string field--label-above"> <div class="field__label">Source Name</div> <div class="field__item">BMJ PDF</div> </div> <div class="field field--name-field-daq-source-url field--type-string field--label-above"> <div class="field__label">Source URL</div> <div class="field__item">https://www.epocrates.com/sites/epocrates/files/2021-09/ParanasalMucormycosisBMJ2109.pdf</div> </div> Mon, 20 Sep 2021 23:55:27 +0000 rray 184001 at http://prod.caas.epocrates.com T http://prod.caas.epocrates.com/node/183996 <span class="field field--name-title field--type-string field--label-hidden">T</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/1126" typeof="schema:Person" property="schema:name" datatype="" content="hgreaney@athenahealth.com">hgreaney@athen…</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 09/20/2021 - 18:57</span> <div class="field field--name-field-g-abbrev-desc field--type-string field--label-above"> <div class="field__label">Description</div> <div class="field__item">temperature</div> </div> Mon, 20 Sep 2021 21:57:02 +0000 hgreaney@athenahealth.com 183996 at http://prod.caas.epocrates.com SOC http://prod.caas.epocrates.com/node/183991 <span class="field field--name-title field--type-string field--label-hidden">SOC</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/1126" typeof="schema:Person" property="schema:name" datatype="" content="hgreaney@athenahealth.com">hgreaney@athen…</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 09/20/2021 - 18:56</span> <div class="field field--name-field-g-abbrev-desc field--type-string field--label-above"> <div class="field__label">Description</div> <div class="field__item">standard of care</div> </div> Mon, 20 Sep 2021 21:56:26 +0000 hgreaney@athenahealth.com 183991 at http://prod.caas.epocrates.com SHEA http://prod.caas.epocrates.com/node/183986 <span class="field field--name-title field--type-string field--label-hidden">SHEA</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/1126" typeof="schema:Person" property="schema:name" datatype="" content="hgreaney@athenahealth.com">hgreaney@athen…</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 09/20/2021 - 18:55</span> <div class="field field--name-field-g-abbrev-desc field--type-string field--label-above"> <div class="field__label">Description</div> <div class="field__item">Society for Healthcare Epidemiology of America</div> </div> Mon, 20 Sep 2021 21:55:38 +0000 hgreaney@athenahealth.com 183986 at http://prod.caas.epocrates.com PR http://prod.caas.epocrates.com/node/183981 <span class="field field--name-title field--type-string field--label-hidden">PR </span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/1126" typeof="schema:Person" property="schema:name" datatype="" content="hgreaney@athenahealth.com">hgreaney@athen…</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 09/20/2021 - 18:54</span> <div class="field field--name-field-g-abbrev-desc field--type-string field--label-above"> <div class="field__label">Description</div> <div class="field__item">per rectum</div> </div> Mon, 20 Sep 2021 21:54:54 +0000 hgreaney@athenahealth.com 183981 at http://prod.caas.epocrates.com PO http://prod.caas.epocrates.com/node/183976 <span class="field field--name-title field--type-string field--label-hidden">PO</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/1126" typeof="schema:Person" property="schema:name" datatype="" content="hgreaney@athenahealth.com">hgreaney@athen…</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 09/20/2021 - 18:54</span> <div class="field field--name-field-g-abbrev-desc field--type-string field--label-above"> <div class="field__label">Description</div> <div class="field__item">orally</div> </div> Mon, 20 Sep 2021 21:54:18 +0000 hgreaney@athenahealth.com 183976 at http://prod.caas.epocrates.com NG http://prod.caas.epocrates.com/node/183971 <span class="field field--name-title field--type-string field--label-hidden">NG </span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/1126" typeof="schema:Person" property="schema:name" datatype="" content="hgreaney@athenahealth.com">hgreaney@athen…</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 09/20/2021 - 18:53</span> <div class="field field--name-field-g-abbrev-desc field--type-string field--label-above"> <div class="field__label">Description</div> <div class="field__item">via nasogastric tube</div> </div> Mon, 20 Sep 2021 21:53:04 +0000 hgreaney@athenahealth.com 183971 at http://prod.caas.epocrates.com